Aelin Therapeutics

Foundation date

06/12/2017

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Aelin Therapeutics is a biopharmaceutical company that has secured a 27 M€ investment to pioneer
peptide-based novel modalities to create a powerful first-in-class antibiotics and agents against high value undruggable human targets. 

Upcoming events

Latest news

  • reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase

    Thursday October 21st 2021

  • Mithra announces Estelle® launch in Belgium

    Thursday October 21st 2021

  • Biotalys awarded multi-year grant to develop new biological solutions for cowpea and other legumes

    Wednesday October 20th 2021